Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.

A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.

Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.

Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).

Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.

Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.

David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.

A panel of experts explain how they approach CNS prophylaxis in DLBCL.

Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.

Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

Factors that should be considered when evaluating patients with relapsed/refractory follicular lymphoma for CAR T-cell therapy.

Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.

Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.

Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).

An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.

Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.

The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.

Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.